Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-20

Clinical Trial Update: Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port [NA]

View source ↗

Summary

A terminated safety study evaluating the combination of Symlin with insulin in patients using a multiple injection port; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Symlin (pramlintide)

Snippet

Sponsor: Texas Diabetes & Endocrinology, P.A. | Conditions: Type 1 Diabetes, Type 2 Diabetes | NA | Status: TERMINATED | Results posted: 2020-10-20